Protocol Ledger

NCT06644417 · Phase II · COMPLETED

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Interventional Phase II clinical trial protocol NCT06644417 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-14 Enrollment: 122 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06644417
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)122 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06644417
Protocol FieldVerified Registry Value
NCT IdentifierNCT06644417
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment122 participants (ACTUAL)
Registered Start Date2024-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI